Dapagliflozin May Benefit Hospitalized COVID-19 Patients

Sodium-glucose cotransporter (SGLT) 2 inhibitor named dapagliflozin was well-tolerated regardless of kidney function, but did not significantly lower patients' risk of organ failure, kidney problems, or death compared with placebo.

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

COVID-19 Affects Multiple Organ Systems

Because COVID-19 affects multiple organ systems, Hiddo Lambers Heerspink, PhD, PharmD, and his colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19) trial to assess the efficacy and safety of the SGLT2 inhibitor dapagliflozin in 1,250 patients with cardio-metabolic risk factors acutely hospitalized with COVID-19.

‘DARE-19 trial reinforced the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19.’

Dapagliflozin was well-tolerated regardless of patients' kidney function but compared with placebo, it did not result in a significant risk reduction in the primary outcomes of organ dysfunction or death, or improvement in recovery.

Dapagliflozin also did not result in a significant risk reduction in the secondary composite kidney outcome of a composite acute kidney injury, kidney replacement therapy, or death.

"These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of acute kidney injury," said Dr. Heerspink.

An accompanying editorial notes that DARE-19 was a neutral trial for all of the outcomes it assessed, both individually and collectively.

"Nevertheless, DARE-19 was a positive trial from the perspective of the safety of using an SGLT2 inhibitor while experiencing acute illness in patients with either preserved or reduced kidney function," the authors wrote.

Source: Medindia